Arlington Capital Partners completed the acquisition of avian vaccine services business of Charles River Laboratories.

Arlington Capital Partners, a private equity firm, completed the acquisition of avian vaccine services business of Charles River Laboratories, a pharmaceutical company. Financial terms were not disclosed. “Identifying and investing behind mission-critical inputs within the biologic manufacturing end market has long been an area of focus for Arlington. Over its 60+ year history, AVS Bio has established itself as the global leader in its market with an extensive domestic manufacturing footprint and an unmatched reputation for quality, biosecurity, and reliability. We are eager to partner with current management to not only establish the Company as a standalone entity, but also capture the opportunities we have collectively identified to produce additional growth through both new product development and strategic acquisitions," Malcolm Little, Arlington Partner.